Lowest Price Guaranteed
Pages
174
Last Updated
August 2026
View Count
15311
EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATASET
1.1. Analysis Notes
1.2. Innovators Landscape
1.3. Products Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. Appendices
2. FUNDING AND INVESTMENT ANALYSIS
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in RNA Therapeutics
2.4 Appendices
3. COMPANY VALUATION ANALYSIS
3.1. Analysis Notes
3.2. Sample Data Analysis
3.3. Company Valuation
3.4. Appendices
4. FUNDAMENTAL FINANCIAL ANALYSIS
4.1. Analysis Notes
4.2. Summary Dashboard
4.3. Company Fundamentals
4.4. Fundamental Analysis
4.4.1. Financial Ratios
4.4.4.1. Liquidity Ratios
4.4.4.2. Financial and Business Risk Ratios
4.4.4.3. Turnover / Efficiency Ratios
4.4.4.4. Profitability Ratios
4.4.4.4. Market Value Ratios
4.4.4.5. Stability Ratios
4.5. Appendices
5. TECHNICAL FINANCIAL ANALYSIS
5.1. Analysis Notes
5.2. Key Highlights
5.3. Open High Low Close Chart / Stock Price & Volume Traded (Last 100 Days)
5.4. 5 Day Moving Average (Buy & Sell Signals)
5.5. 10 Day Moving Average (Buy & Sell Signals)
5.6. 50 Day Moving Average (Buy & Sell Signals)
5.7. Bollinger Bands®
5.8. Relative Strength Index
5.9. Average Directional Index
5.10. Commodity Channel Index
5.11. Williams R
5.12. Moving Average Convergence Divergence (MACD)
5.13. Appendices
6. BUSINESS RISK ASSESSMENT
6.1. Analysis Notes
6.2. Business Risk Data
6.3. Appendices
7. MARKET FORECAST AND OPPORTUNITY ANALYSIS
7.1. Analysis Notes
7.2. Market Forecast and Opportunity Analysis: Summary
7.3. Market Forecast and Opportunity Analysis: Base Scenario
7.4. Market Forecast and Opportunity Analysis: Conservative Scenario
7.5. Market Forecast and Opportunity Analysis: Optimistic Scenario
8. ANALYSIS OF RETURNS ON INVESTMENT
8.1. Analysis Notes
8.2. Estimated RoI for Investors in Company A
8.3. Estimated RoI for Investors in Company B
8.4. Estimated RoI for Investors in Company C
POWERPOINT DELIVERABLE
1. CONTEXT
2. PROJECT APPROACH
3. PROJECT OBJECTIVES
4. EXECUTIVE SUMMARY
Section I: Introduction to RNA Therapeutics and Innovators Landscape
5. THE RNA THERAPEUTICS MARKET
5.1. Overview
5.2. Types of RNA Therapeutics
5.3. Historical Development
5.4. Applications of RNA Therapeutics
5.5. Benefits of RNA Therapeutics
5.6. Challenges Associated with RNA Therapeutics
5.7. Contemporary Sentiments and Expert Opinions
6. RNA THERAPEUTICS: INNOVATORS LANDSCAPE
6.1. Methodology
6.2. Innovators in the RNA Therapeutics Market
6.3. Analysis of Innovators Landscape
6.4. Concluding Remarks
7. RNA THERAPEUTICS: PRODUCTS LANDSCAPE AND COMPANY HEALTH INDEXING
7.1. List of RNA Therapeutics
7.2. Analysis of Products Landscape
7.3. Company Health Indexing Methodology
7.4. Company Health Indexing Scoring
7.5. Company Health Indexing
8. VALUE PROPOSITION ANALYSIS
8.1. Overview and Methodology
8.2. Value Proposition Analysis: Therapy-related Aspect
8.3. Value Proposition Analysis: Developer-related Aspect
8.4. Value Proposition Analysis: Technology-related Aspect
8.5. Value Proposition Analysis: Patient-related Aspect
8.6. Concluding Remarks
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
9.3. Concluding Remarks
Section II: Analysis of Investments and Company Valuation
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography and Most Active Companies
10.4. Analysis of Trends Associated with Individual Funding Categories
10.5. Funding and Investments Summary
11. COMPANY VALUATION ANALYSIS
11.1. Overview and Methodology
11.2. Valuation of Public Companies
11.3. Company Valuation: Based on Company Size
11.4. Company Valuation: Based on Latest Stage of Financing
11.5. Company Valuation: Based on Company Size and Latest Stage of Funding
Section III: Financial Analysis and Assessment of Business Risks
12. FINANCIAL ANALYSIS OF PUBLIC VENTURES
12.1. Fundamental Financial Analysis Overview
12.2. Financial Ratios (Interpretation Guide)
12.3. Fundamental Financial Analysis: List of Public Companies
12.4. Case Study 1
12.5. Technical Financial Analysis Overview
12.6. Technical Indicators (Interpretation Guide)
12.7. Technical Financial Analysis: List of Public Companies
12.8. Case Study 2
13. COMPANY PROFILES OF PUBLIC VENTURES
13.1. Arbutus Biopharma
13.1.1. Key Highlights
13.1.1.1. Company Overview
13.1.1.2. Insights from Balance Sheet
13.1.1.3. Key Executive Team
13.1.1.4. Recent Developments
13.1.2. Key Financial Details
13.1.2.1. Company Investments
13.1.2.2. Company Fundamentals
13.1.2.3. Company Technicals
13.2. Arcturus Therapeutics
13.2.1. Key Highlights
13.2.1.1. Company Overview
13.2.1.2. Insights from Balance Sheet
13.2.1.3. Key Executive Team
13.2.1.4. Recent Developments
13.2.2. Key Financial Details
13.2.2.1. Company Investments
13.2.2.2. Company Fundamentals
13.2.2.3. Company Technicals
13.3. GreenLight Biosciences
13.3.1. Key Highlights
13.3.1.1. Company Overview
13.3.1.2. Insights from Balance Sheet
13.3.1.3. Key Executive Team
13.3.1.4. Recent Developments
13.3.2. Key Financial Details
13.3.2.1. Company Investments
13.3.2.2. Company Fundamentals
13.3.2.3. Company Technicals
13.4. Gritstone bio
13.4.1. Key Highlights
13.4.1.1. Company Overview
13.4.1.2. Insights from Balance Sheet
13.4.1.3. Key Executive Team
13.4.1.4. Recent Developments
13.4.2. Key Financial Details
13.4.2.1. Company Investments
13.4.2.2. Company Fundamentals
13.4.2.3. Company Technicals
13.5. IVERIC bio
13.5.1. Key Highlights
13.5.1.1. Company Overview
13.5.1.2. Insights from Balance Sheet
13.5.1.3. Key Executive Team
13.5.1.4. Recent Developments
13.5.2. Key Financial Details
13.5.2.1. Company Investments
13.5.2.2. Company Fundamentals
13.5.2.3. Company Technicals
13.6. Moderna
13.6.1. Key Highlights
13.6.1.1. Company Overview
13.6.1.2. Insights from Balance Sheet
13.6.1.3. Key Executive Team
13.6.1.4. Recent Developments
13.6.2. Key Financial Details
13.6.2.1. Company Investments
13.6.2.2. Company Fundamentals
13.6.2.3. Company Technicals
13.7. Omega Therapeutics
13.7.1. Key Highlights
13.7.1.1. Company Overview
13.7.1.2. Insights from Balance Sheet
13.7.1.3. Key Executive Team
13.7.1.4. Recent Developments
13.7.2. Key Financial Details
13.7.2.1. Company Investments
13.7.2.2. Company Fundamentals
13.7.2.3. Company Technicals
13.8. Phio Pharmaceuticals
13.8.1. Key Highlights
13.8.1.1. Company Overview
13.8.1.2. Insights from Balance Sheet
13.8.1.3. Key Executive Team
13.8.1.4. Recent Developments
13.8.2. Key Financial Details
13.8.2.1. Company Investments
13.8.2.2. Company Fundamentals
13.8.2.3. Company Technicals
13.9. Regulus Therapeutics
13.9.1. Key Highlights
13.9.1.1. Company Overview
13.9.1.2. Insights from Balance Sheet
13.9.1.3. Key Executive Team
13.9.1.4. Recent Developments
13.9.2. Key Financial Details
13.9.2.1. Company Investments
13.9.2.2. Company Fundamentals
13.9.2.3. Company Technicals
13.10. Vir Biotechnology
13.10.1. Key Highlights
13.10.1.1. Company Overview
13.10.1.2. Insights from Balance Sheet
13.10.1.3. Key Executive Team
13.10.1.4. Recent Developments
13.10.2. Key Financial Details
13.10.2.1. Company Investments
13.10.2.2. Company Fundamentals
13.10.2.3. Company Technicals
14. BUSINESS RISK ASSESSMENT
14.1. Overview and Methodology
14.2. Operations-related Risks
14.3. Business-related Risks
14.4. Financial / Asset-related Risks
14.5. Product / Technology-related Risks
14.6. Industry Specific Risks
14.7. Other Risks
14.8. Summary of Business Risk Assessment
Section IV: Market Forecast and Opportunity Analysis
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Overview and Methodology
15.2. Global RNA Therapeutics Market, 2023-2035
15.2.1. RNA Therapeutics Market: Analysis by Type of Therapy, 2023 and 2035
15.2.1.1. RNA Therapeutics Market for miRNA Therapies, 2023-2035
15.2.1.2. RNA Therapeutics Market for siRNA Therapies, 2023-2035
15.2.1.3. RNA Therapeutics Market for mRNA Therapies, 2023-2035
15.2.1.4. RNA Therapeutics Market for mRNA Vaccines, 2023-2035
15.2.1.5. RNA Therapeutics Market for RNA Aptamers, 2023-2035
15.2.2. RNA Therapeutics Market: Analysis by Therapeutic Area, 2023 and 2035
15.2.2.1. RNA Therapeutics Market for Infectious Diseases, 2023-2035
15.2.2.2. RNA Therapeutics Market for Metabolic Disorders, 2023-2035
15.2.2.3. RNA Therapeutics Market for Oncological Disorders, 2023-2035
15.2.2.4. RNA Therapeutics Market for Genetic Disorders, 2023-2035
15.2.2.5. RNA Therapeutics Market for Other Disorders, 2023-2035
15.2.3. RNA Therapeutics Market: Analysis by Route of Administration, 2023 and 2035
15.2.3.1. RNA Therapeutics Market for Intramuscular Therapies, 2023-2035
15.2.3.2. RNA Therapeutics Market for Intravenous Therapies, 2023-2035
15.2.3.3 RNA Therapeutics Market for Intranasal Therapies, 2023-2035
15.2.3.4 RNA Therapeutics Market for Other Routes of Administration, 2023-2035
15.2.4. RNA Therapeutics Market: Analysis by Key Geographies, 2023 and 2035
15.2.4.1. RNA Therapeutics Market in North America, 2023-2035
15.2.4.2. RNA Therapeutics Market in Europe, 2023-2035
15.2.4.3. RNA Therapeutics Market in Asia, 2023-2035
15.2.4.3. RNA Therapeutics Market in Latin America, 2023-2035
15.2.4.3. RNA Therapeutics Market in Middle East and North Africa, 2023-2035
15.2.4.3. RNA Therapeutics Market in Rest of the World, 2023-2035
Section V: Analysis of Returns on Investment and Key Acquisition Targets
16. ANALYSIS OF RETURNS ON INVESTMENT
16.1. Overview and Methodology
16.2. Case Studies
16.2.1. Avidity Biosciences
16.2.2. BioNTech
16.2.3. GreenLight Biosciences
16.2.4. Gritstone bio
16.2.5. IVERIC bio
16.2.6. Moderna
16.2.7. Regulus Therapeutics
16.2.8. Vir Biotechnology
16.3. Concluding Remarks
17. KEY ACQUISITION TARGETS
17.1. Overview
17.2. List of Key Acquisition Targets
17.3. Concluding Remarks
18. CONCLUSION
19. APPENDICES
Figure 5.1. RNA Therapeutics: Key Definitions and Background
Figure 5.2. RNA Therapeutics: Types of Therapies and Key Industry Players
Figure 5.3. RNA Therapeutics: Key Historical Developments
Figure 5.4. RNA Therapeutics: Key Strategic Initiatives of Industry Players
Figure 5.5. RNA Therapeutics: Key Marketed Products and Current Unmet Needs
Figure 6.1. Innovators Landscape: Distribution by Year of Establishment
Figure 6.2. Innovators Landscape: Distribution by Type of Venture
Figure 6.3. Innovators Landscape: Distribution by Company Size
Figure 6.4. Innovators Landscape: Distribution by Geography
Figure 7.1. Products Landscape: Distribution of Innovators by Number of Products
Figure 7.2. Products Landscape: Distribution by Type of Products
Figure 7.3. Products Landscape: Distribution of Products by Phase of Development
Figure 7.4. Products Landscape: Distribution of Products by Route of Administration
Figure 7.5. Products Landscape: Distribution of Products by Therapeutic Area
Figure 8.1. Therapy-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.2. Therapy-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.3. Developer-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.4. Developer-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.5. Technology-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.6. Technology-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.7. Patient-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.8. Patient-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.9. Summary of Value Proposition Analysis
Figure 9.1. Competitiveness Analysis: Companies based in North America (Peer Group I)
Figure 9.2. Competitiveness Analysis: Companies based in Europe (Peer Group II)
Figure 9.3. Competitiveness Analysis: Companies based in Asia and Rest of the World (Peer Group III)
Figure 10.1. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances and Amount Invested, 2011-2022
Figure 10.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.3. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Figure 10.4. Funding and Investment Analysis: Distribution of Instances and Amount Invested by Region
Figure 10.5. Funding and Investment Analysis: Most Active Players by Number of Instances
Figure 10.6. Funding and Investment Analysis: Most Active Players by Amount Raised
Figure 10.7. Awards / Grants: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.8. Awards / Grants: Distribution of Amount Invested by Region
Figure 10.9. Awards / Grants: Most Active Investors by Amount Invested
Figure 10.10. Seed Funding: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.11. Seed Funding: Distribution of Amount Invested by Region
Figure 10.12. Seed Funding: Most Active Investors by Amount Invested
Figure 10.13. Venture (Series A): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.14. Venture (Series A): Distribution of Amount Invested by Region
Figure 10.15. Venture (Series A): Most Active Investors by Amount Invested
Figure 10.16. Venture (Series B): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.17. Venture (Series B): Distribution of Amount Invested by Region
Figure 10.18. Venture (Series B): Most Active Investors by Amount Invested
Figure 10.19. Venture (Series C): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.20. Venture (Series C): Distribution of Amount Invested by Region
Figure 10.21. Venture (Series C): Most Active Investors by Amount Invested
Figure 10.22. Venture (Series D, E, F, G, H, and Unknown) Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.23. Venture (Series D, E, F, G, H, and Unknown): Distribution of Amount Invested by Region
Figure 10.24. Venture (Series D, E, F, G, H, and Unknown): Most Active Investors by Amount Invested
Figure 10.25. Public Offerings: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.26. Public Offerings: Distribution of Amount Invested by Region
Figure 10.27. Public Offerings: Publicly Listed Players
Figure 10.28. Private Placements: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.29. Private Placements: Distribution of Amount Invested by Region
Figure 10.30. Private Placements: Most Active Investors by Amount Invested
Figure 10.31. Debt Financing: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.32. Debt Financing: Distribution of Amount Invested by Region
Figure 10.33. Debt Financing: Most Active Investors by Amount Invested
Figure 10.34. Capital Investments in RNA Therapeutics: Summary of Investments, 2011-2022
Figure 12.1. Arbutus Biopharma: Annual Revenues and Key Balance Sheet Parameter-related Trends, 2017-2022
Figure 12.2. Arbutus Biopharma: Liquidity Ratios, 2017-2022
Figure 12.3. Arbutus Biopharma: Financial and Business Risk Ratios and Turnover / Efficiency Ratios, 2017-2022
Figure 12.4. Arbutus Biopharma: Profitability Ratios, 2017-2022
Figure 12.5. Arbutus Biopharma: Market Value Ratios and Stability Ratios, 2017-2022
Figure 12.6. Arcturus Therapeutics: Stock Price (Candlestick Chart) and Volume Traded
Figure 12.7. Arcturus Therapeutics: 5-Day Moving Average
Figure 12.8. Arcturus Therapeutics: 10-Day Moving Average
Figure 12.9. Arcturus Therapeutics: 50-Day Moving Average
Figure 12.10. Arcturus Therapeutics: Bollinger Band
Figure 12.11. Arcturus Therapeutics: Relative Strength Index
Figure 12.12. Arcturus Therapeutics: Commodity Channel Index (CCI)
Figure 12.13. Arcturus Therapeutics: Moving Average Convergence / Divergence (MACD)
Figure 12.14. Arcturus Therapeutics: Williams’ R Analysis
Figure 12.15. Arcturus Therapeutics: Average Directional Index (ADX)
Figure 13.1. Arbutus Biopharma: Company Fundamentals
Figure 13.2. Arbutus Biopharma: Trend of Stock Prices Since Initial Public Offering
Figure 13.3. Arcturus Therapeutics: Company Fundamentals
Figure 13.4. Arcturus Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.5. GreenLight Biosciences: Company Fundamentals
Figure 13.6. GreenLight Biosciences: Trend of Stock Prices Since Initial Public Offering
Figure 13.7. Gritstone bio: Company Fundamentals
Figure 13.8. Gritstone bio: Trend of Stock Prices Since Initial Public Offering
Figure 13.9. IVERIC bio: Company Fundamentals
Figure 13.10. IVERIC bio: Trend of Stock Prices Since Initial Public Offering
Figure 13.11. Moderna: Company Fundamentals
Figure 13.12. Moderna: Trend of Stock Prices Since Initial Public Offering
Figure 13.13. Omega Therapeutics: Company Fundamentals
Figure 13.14. Omega Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.15. Phio Pharmaceuticals: Company Fundamentals
Figure 13.16. Phio Pharmaceuticals: Trend of Stock Prices Since Initial Public Offering
Figure 13.17. Regulus Therapeutics: Company Fundamentals
Figure 13.18. Regulus Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.19. Vir Biotechnology: Company Fundamentals
Figure 13.20. Vir Biotechnology: Trend of Stock Prices Since Initial Public Offering
Figure 14.1. Business Risk Assessment: Operations-related Risks
Figure 14.2. Business Risk Assessment: Business-related Risks
Figure 14.3. Business Risk Assessment: Financial / Asset-related Risks
Figure 14.4. Business Risk Assessment: Product / Technology-related Risks
Figure 14.5. Business Risk Assessment: Industry Specific Risks
Figure 14.6. Business Risk Assessment: Other Risks
Figure 14.7. Summary of Business Risk Assessment
Figure 15.1. RNA Therapeutics Market: Forecast, 2023-2035 (USD Million)
Figure 15.2. RNA Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
Figure 15.3. RNA Therapeutics Market for miRNA Therapies, 2023-2035 (USD Million)
Figure 15.4. RNA Therapeutics Market for siRNA Therapies, 2023-2035 (USD Million)
Figure 15.5 RNA Therapeutics Market for mRNA Therapies, 2023-2035 (USD Million)
Figure 15.6. RNA Therapeutics Market for mRNA Vaccines, 2023-2035 (USD Million)
Figure 15.7. RNA Therapeutics Market for RNA Aptamers, 2023-2035 (USD Million)
Figure 15.8. RNA Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
Figure 15.9. RNA Therapeutics Market for Infectious Diseases, 2023-2035 (USD Million)
Figure 15.10. RNA Therapeutics Market for Metabolic Disorders, 2023-2035 (USD Million)
Figure 15.11. RNA Therapeutics Market for Oncological Disorders, 2023-2035 (USD Million)
Figure 15.12. RNA Therapeutics Market for Genetic Disorders, 2023-2035 (USD Million)
Figure 15.13. RNA Therapeutics Market for Other Disorders, 2023-2035 (USD Million)
Figure 15.14. RNA Therapeutics Market: Distribution by Route of Administration, 2023 and 2035
Figure 15.15. RNA Therapeutics Market for Intramuscular Therapies, 2023-2035 (USD Million)
Figure 15.16. RNA Therapeutics Market for Intravenous Therapies, 2023-2035 (USD Million)
Figure 15.17. RNA Therapeutics Market for Intranasal Therapies, 2023-2035 (USD Million)
Figure 15.18. RNA Therapeutics Market for Other Routes of Administration, 2023-2035 (USD Million)
Figure 15.19. RNA Therapeutics Market: Distribution by Key Geographies, 2023 and 2035
Figure 15.20. RNA Therapeutics Market in North America, 2023-2035 (USD Million)
Figure 15.21. RNA Therapeutics Market in Europe, 2023-2035 (USD Million)
Figure 15.22. RNA Therapeutics Market in Asia, 2023-2035 (USD Million)
Figure 15.23. RNA Therapeutics Market in Latin America, 2023-2035 (USD Million)
Figure 15.24. RNA Therapeutics Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 15.25. RNA Therapeutics Market in Rest of the World, 2023-2035 (USD Million)
Figure 16.1. Avidity Biosciences: Returns on Investment Reported by Selected Stakeholdersand Historical Funding Activity
Figure 16.2. BioNTech: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.3. GreenLight Biosciences: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.4. Gritstone bio: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.5. IVERIC bio: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.6. Moderna: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.7. Regulus Therapeutics: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.8. Vir Biotechnology: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 17.1. Key Acquisition Targets: Comparison of Scores with Overall Dataset
Figure 17.2. Key Acquisition Targets: Comparison based on Qualifying Parameters (I/IV)
Figure 17.3. Key Acquisition Targets: Comparison based on Qualifying Parameters (II/IV)
Figure 17.4. Key Acquisition Targets: Comparison based on Qualifying Parameters (III/IV)
Figure 17.5. Key Acquisition Targets: Comparison based on Qualifying Parameters (IV/IV)
Figure 18.1. Concluding Landscape: North America
Figure 18.2. Concluding Landscape: Europe
Figure 18.3. Concluding Landscape: Asia and Rest of the World
Table 6.1. Key Innovators in the RNA Therapeutics Market
Table 7.1. Products Offered by Innovators in the RNA Therapeutics Market
Table 7.2. RNA Therapeutics Developers: Company Health Indexing (I/V)
Table 7.3. RNA Therapeutics Developers: Company Health Indexing (II/V)
Table 7.4. RNA Therapeutics Developers: Company Health Indexing (III/V)
Table 7.5. RNA Therapeutics Developers: Company Health Indexing (IV/V)
Table 7.6. RNA Therapeutics Developers: Company Health Indexing (V/V)
Table 11.1. Valuation of Public Companies: Sample Dataset
Table 11.2. Company Valuation: Based on Company Size
Table 11.3. Company Valuation: Based on Latest Stage of Financing
Table 11.4. Company Valuation: Based on Company Size and Latest Stage of Funding
Table 12.1. Fundamental Financial Analysis: Information on Publicly Listed RNA Therapeutics Developers
Table 12.2. Technical Financial Analysis: Information on Publicly Listed RNA Therapeutics Developers
Table 17.1. RNA Therapeutics Developers: Likely Acquisition Targets (Company Strength)
Table 17.2. RNA Therapeutics Developers: Likely Acquisition Targets (Value Proposition)
Please reach out to our team for the details.
Source 1: https://www.biopharminternational.com/view/the-covid-19-pandemic-and-its-positive-impact-on-rna-drug-development
Source 2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627066/